Back to search results

Hemp Product and Clopidogrel Interaction Study

This study is looking at how a hemp product containing cannabidiol (CBD) affects the levels of clopidogrel in your blood. Clopidogrel is a medication often prescribed to prevent blood clots. Researchers want to understand if taking CBD from hemp changes how your body processes clopidogrel. This information will help doctors advise patients on using CBD safely alongside their medications. The study plans to enroll 24 healthy individuals between 21 and 64 years old who have used hemp or cannabis before. You must also have a specific genetic profile (CYP2C19 normal, rapid, or ultra-rapid metabolizer) and not be taking other medications that could interfere. The study's status is currently unclear.

Study design
This is an interventional study planning to enroll 24 participants. It will test the effects of cannabidiol (30 mg) in the form of an orally administered hemp oil softgel and 75 mg oral clopidogrel.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures the AUC (area under the curve) ratio of clopidogrel active metabolite from 0-24 hours, suggesting a follow-up period of at least 24 hours.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06692933

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Recruiting
EARLY_PHASE1Ages 21–64InterventionalBasic science
Washington State University
~24 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Cannabidiol in the form of hempClopidogrel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
AUC ratio of clopidogrel active metabolite
Measured over 0-24 hours

Conditions

Interaction

Explore related trials

Healthy VolunteerCytochrome P450 2C19

Where it's being run

1 sites across 1 states
Washington1

Who to contact

Mary F Paine, RPh, PhD
[email protected]
509-358-7759
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

21-64 years old and healthy;
Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;
Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
Have taken hemp or cannabis (in any form) before and tolerated it well;
Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study;
Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks;
Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day;
Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day;
Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study;
Have the ability to and are willing to comply with the requirements of the study;
Geographically located within a 40-mile radius of Spokane and have the time to participate and;
Can read and speak English

Exclusion

Under the age of 21 or over the age of 64;
Any major illness;
Pregnant or nursing;
History of allergy or intolerance to cannabis or clopidogrel;
Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
Never taken cannabis (in any form) before;
Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data;
Currently using or have recently used drugs or other illicit substances for recreational purposes;
Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks;
Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or;
Unable to read and speak English

What this trial measures

  • AUC ratio of clopidogrel active metabolite0-24 hours

    Ratio of the area under the plasma concentration vs. time curve of the active metabolite of clopidogrel in the presence to absence of hemp